CONNECT WITH US:
May, 22 2017 12:00 JST
Singapore eDevelopment Ltd
Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform
- Nobel Prize nominee Daryl Thompson to lead research, conducted by subsidiary Global BioLife Inc., supported by Charles River Laboratories
- Six month target for validating lab data, twelve month target for completion of platform
SINGAPORE, May, 22 2017 - (ACN Newswire) - Singapore eDevelopment Ltd ("SeD"), through subsidiary Global BioLife Inc. ("Global BioLife"), has initiated advanced research on a new universal therapeutic drug platform known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee Mr Daryl Thompson.
SGX-listed SeD (SP:SGE) said Mr Thompson would leverage his expertise in organic and carbohydrate chemistry and the use of pandemic technology in combating the Ebola virus in the development of Linebacker. Unlike traditional approaches to curing individual diseases with specific drugs, the Linebacker platform seeks a breakthrough option for multiple diseases to be cured. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.
Mr Thompson will lead the research, to be conducted by Global BioLife, in his capacity as Director of Scientific Initiatives. Global BioLife is an 80%-held subsidiary of SeD's wholly-owned subsidiary, Global BioMedical Inc. The remaining stake in Global BioLife is held in equal proportions by Mr Thompson's GRDG Sciences LLC and ASX-listed Holista CollTech Limited.
Mr Thompson was nominated for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his expertise to initiate research regarding universal therapeutics to cure the world's deadliest diseases. Mr Scott Truesdell, Research Coordinator and Special Projects Leader at Global BioLife, will execute the research on the Linebacker platform.
Global BioLife has engaged NYSE-listed Charles River Laboratories International, Inc., which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
Mr Thompson said, "We expect to obtain validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be completed within twelve months. We have a unique patented technology and are already getting interest from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available."
"Global BioLife recognizes the need for affordable cures to emerging pandemics and we will leverage the team's deep expertise to develop this new universal therapeutic drug platform," said Dr Tang Peihong, Global BioLife Director and CEO. Dr Tang has a Ph.D. in Chemical Engineering and was selected as National Distinguished Expert in China's Thousand Talents Plan in 2012.
GRDG Sciences LLC is a natural products discovery drug research company formed in Florida, USA by Mr Thompson, a natural products scientist. GRDG Sciences works with multiple global institutions such as Charles River. Holista CollTech Ltd is a research-driven biotech company that resulted from the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. It is dedicated to delivering first-class natural ingredients and wellness products (www.holista.com).
About Singapore eDevelopment Limited
Incorporated on 9 September 2009, and listed on the Singapore Exchange Catalist (SGX:40V) in July 2010 (SP: SGE; SINE), Singapore eDevelopment is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) Information Technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg.
Issued on behalf of the Company:
WeR1 Consultants Pte Ltd
Mr Ian Lau
T: +65 6737 4844
Source: Singapore eDevelopment Ltd
Sectors: Investors/Exchanges, Daily Finance, BioTech, HealthCare, Alternatives
Copyright ©2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Honda's Cumulative Worldwide Power Products Production Reaches 150 million Units
Sep 19, 2019 20:20 JST
Eisai to Present Latest Data on Lemborexant at World Sleep Congress
Sep 19, 2019 20:06 JST
Toyota to Invest R$1 Billion in its Plant in Brazil to Produce New Vehicle
Sep 19, 2019 14:11 JST
Fujitsu Launches IoT Measuring device for more efficient measurements in the Apparel Industry
Sep 19, 2019 11:41 JST
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019
Sep 18, 2019 21:40 JST
Mitsubishi Motors Hosts World Debuts of Small Electric SUV Concept Car at 46th Tokyo Motor Show 2019
Sep 18, 2019 21:31 JST
KDDI Joins Merpay, LINE Pay, and NTT DOCOMO's Merchant Alliance "Mobile Payment Alliance (MoPA)"
Sep 18, 2019 21:19 JST
DOCOMO to Commence Deployment of World's First 4G/5G Multi-vendor Radio Access Network Conforming to O-RAN Specifications
Sep 18, 2019 15:12 JST
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Sep 18, 2019 14:58 JST
MHI-MME to Take Over Production of MET Turbochargers
Sep 18, 2019 14:46 JST
KAHRAMAA, QEWC and MHPS Sign MOU on Internship Program for Young Qatari Engineers
Sep 18, 2019 14:41 JST
Toyota Installs Stationary Fuel Cell Generator Based on the Mirai FC System at its Honsha Plant in Japan
Sep 18, 2019 13:34 JST
Fujitsu Develops Digitization Technology to Quantify Various Walking Characteristics Resulting from Diseases
Sep 18, 2019 11:30 JST
Toyota Injects $391 Million New Investment in its San Antonio Assembly Plant
Sep 18, 2019 07:54 JST
Hitachi to Integrate Hitachi Vantara and Hitachi Consulting to Accelerate Global Expansion of Hitachi's Social Innovation Business and Digital Growth
Sep 18, 2019 07:42 JST
Eisai Receives IIA Japan Chairman's Award of Institute of Internal Auditors - Japan
Sep 17, 2019 16:42 JST
Toyota Rolls Out Completely Redesigned Corolla, Corolla Touring, and Unveils Improvements to the Corolla Sport in Japan
Sep 17, 2019 13:16 JST
A Power Stage Win and Crucial Points for TOYOTA GAZOO Racing
Sep 17, 2019 09:10 JST
MHI Included in Dow Jones Sustainability Asia Pacific Index for Third Consecutive Year
Sep 17, 2019 01:00 JST
Mitsubishi Motors to Begin Producing the XPANDER in Vietnam in 2020
Sep 16, 2019 09:05 JST
More Latest Release >>
Global BioLife Inc.'s Naturally Modified Sugar Laetose(TM) Unveiled at Harvard Global Health Summit
July 24 2019 15:00 JST
Global BioLife's new mosquito repellent formula performs well against mosquitos in independent testing
June 12 2019 14:00 JST
Singapore eDevelopment subsidiary Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
January 28 2019 12:00 JST
Singapore eDevelopment Subsidiary, Global BioLife, Proudly Announces Presentation of Parkinson's Research at Neuroscience 2018
November 07 2018 19:00 JST
Singapore eDevelopment Announces Corporate and Business Update
June 18 2018 19:00 JST
Singapore Exchange-Listed Singapore eDevelopment Limited's U.S. Biomedical Subsidiary Global BioLife, Inc. Develops Low Glycemic Modified Sugar
May 31 2018 18:00 JST
Singapore eDevelopment biomedical subsidiary confirms LB2 efficacy against Ebola
March 01 2018 14:00 JST
Singapore eDevelopment's Biomedical Subsidiary Confirms 100% Repellency of 3F Mosquito Fragrance
November 01 2017 18:00 JST
SGX-Listed Singapore eDevelopment's Global BioLife Inc Develops Breakthrough Modified Sugar
October 24 2017 18:00 JST
Singapore eDevelopment's Global BioLife and U.S.-based Chemia Corporation to Develop Functional Fragrances to Fight Mosquito-Borne Diseases
August 15 2017 19:00 JST
More Press release >>